GO:0070266 necroptotic process: Programmed Necrotic Cell Death, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0070266 necroptotic process is a programmed necrotic cell death pathway triggered by death receptor or Toll-like receptor signaling and critically dependent on RIPK1/RIPK3 kinase activity and MLKL.
• Necroptosis proceeds in two phases: a signaling phase that assembles the necrosome, and an execution phase in which MLKL permeabilizes the plasma membrane.
• ZBP1 and other nucleic-acid sensors can activate RIPK3-dependent necroptosis in response to mitochondrial DNA release or stress granule formation.
• Necroptosis is implicated in tumor progression, neurodegeneration, inflammatory bowel disease, colorectal cancer, and testicular aging.
• PARP5A/RNF146 phase separation and SIGLEC12-mediated plasma membrane rupture represent newly identified regulatory nodes in necroptotic execution.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are essential for dissecting causal roles of RIPK1, RIPK3, MLKL, ZBP1, and other necroptosis regulators.
Description
Necroptotic process (GO:0070266) is a programmed necrotic cell death process that begins when a cell receives a signal, such as a ligand binding to a death receptor or a Toll-like receptor, and proceeds through a series of biochemical signaling events. Unlike apoptosis, necroptosis is characterized by activation of receptor-interacting serine/threonine-protein kinase 1 and/or 3 (RIPK1/RIPK3) and by critical dependence on mixed lineage kinase domain-like (MLKL), leading to common morphological features of necrotic cell death. The process is divided into a signaling phase and an execution phase, which is triggered by the former. Necroptosis matters for researchers because it sits at the intersection of inflammation, host defense, and cell fate decisions. It is now recognized as a driver of tumor progression and a modulator of cancer therapy responses, and it contributes to neurodegeneration in Alzheimer's disease. In inflammatory bowel disease and colorectal cancer, necroptosis is one of several regulated cell death modalities that shape intestinal injury and tumor biology. Emerging work has also linked necroptotic cell death to non-obstructive azoospermia and testicular aging through stress granule-mediated ZBP1 activation. The pathway is tightly regulated at multiple levels, including post-translational modification of RIPK1, phase separation of PARP5A and RNF146, and plasma membrane rupture mediated by SIGLEC12. Understanding these mechanisms requires integrated genetic, biochemical, and imaging approaches, and CRISPR-based cell models are central to establishing causality for candidate regulators.
necroptotic process At A Glance
| GO ID | GO:0070266 |
|---|---|
| GO term | necroptotic process |
| Ontology | biological_process |
| Synonym | necroptosis; programmed necrosis; programmed necrotic cell death; TNF-induced necroptosis; RIPK1-mediated regulated necrosis; parthanatos; PARP-dependent cell death |
| Major function | Programmed necrotic cell death triggered by death receptor or Toll-like receptor signaling, dependent on RIPK1/RIPK3 and MLKL |
| Key kinases | RIPK1, RIPK3 |
| Key executioner | MLKL |
| Signaling phase | Assembly of the necrosome and activation of RIPK1/RIPK3 |
| Execution phase | MLKL-dependent plasma membrane rupture and cell death |
| Representative triggers | TNF family ligands, Toll-like receptor ligands, nucleic acid sensing via ZBP1 |
What Is GO:0070266?
In our own words, GO:0070266 necroptotic process describes a programmed form of necrotic cell death that is initiated by extracellular signals such as ligands binding to death receptors or Toll-like receptors. The process unfolds through a signaling phase that activates RIPK1 and/or RIPK3 and a downstream execution phase that critically depends on MLKL. The endpoint is cell death with morphological features typical of necrosis. The term encompasses synonyms such as necroptosis, programmed necrosis, TNF-induced necroptosis, and RIPK1-mediated regulated necrosis, and it is distinct from apoptosis and from other regulated cell death modalities such as ferroptosis and pyroptosis.
Why Is necroptotic process Important in Cell Biology?
Necroptotic process is important because it is a genetically encoded cell death program that can be therapeutically modulated in cancer, neurodegeneration, inflammatory bowel disease, and reproductive aging. Its dependence on RIPK1, RIPK3, and MLKL provides defined molecular handles for drug discovery and for CRISPR-based functional genomics. Moreover, necroptosis intersects with innate immune sensing pathways, including ZBP1-dependent detection of mitochondrial DNA and stress granules, linking cell death to inflammation and tissue homeostasis.
• Necroptosis is a major regulated cell death modality distinct from apoptosis and is relevant to tumor progression and therapy.
• RIPK1 and RIPK3 kinase activities are central signaling nodes and are druggable targets.
• MLKL is the essential executioner of necroptotic plasma membrane rupture.
• ZBP1 senses nucleic acids and mitochondrial DNA to trigger RIPK3-mediated necroptosis.
• Necroptosis contributes to neurodegeneration in Alzheimer's disease.
• Necroptosis is implicated in inflammatory bowel disease and colorectal cancer.
• Necroptotic cell death drives testicular aging and non-obstructive azoospermia in models.
• PARP5A and RNF146 phase separation restrains RIPK1-dependent necroptosis.
• SIGLEC12 mediates plasma membrane rupture during necroptotic cell death.
• CRISPR models enable causal testing of necroptosis regulators in disease contexts.
What Happens During necroptotic process?
Initiation by death receptor and Toll-like receptor signaling
In simple terms: A cell receives an external death signal, like TNF binding to its receptor, which sets the necroptosis program in motion.
The necroptotic process begins when a cell receives a signal, for example a ligand binding to a death receptor or to a Toll-like receptor. This extracellular signal initiates a signaling phase that ultimately activates RIPK1 and/or RIPK3. The definition of GO:0070266 explicitly includes activation of necroptosis by extracellular signals, and TNF-induced necroptosis is a canonical trigger.
Necrosome assembly and RIPK1/RIPK3 activation
In simple terms: RIPK1 and RIPK3 come together in a protein complex called the necrosome, where they activate each other.
During the signaling phase, RIPK1 and RIPK3 are recruited into a necrosome complex and become activated. Activation of receptor-interacting serine/threonine-protein kinase 1 and/or 3 is a defining biochemical event of GO:0070266. Post-translational regulation of RIPK1, including phase separation of PARP5A and RNF146, can restrain RIPK1-dependent necroptosis, showing that necrosome assembly is tightly controlled.
MLKL-dependent execution phase
In simple terms: Activated RIPK3 turns on MLKL, which punches holes in the cell membrane and kills the cell.
The execution phase is triggered by the signaling phase and critically depends on MLKL. MLKL is the essential downstream effector whose activation leads to plasma membrane rupture and necrotic cell death. Recent work shows that SIGLEC12 mediates plasma membrane rupture during necroptotic cell death, identifying a new component of the execution machinery.
Nucleic acid sensing and ZBP1-dependent necroptosis
In simple terms: When DNA or RNA sensors like ZBP1 detect misplaced nucleic acids, they can trigger necroptosis through RIPK3.
ZBP1 is a nucleic acid sensor that can activate RIPK3-mediated necroptosis. Sensing of mitochondrial DNA by ZBP1 promotes RIPK3-mediated necroptosis and ferroptosis in response to diquat poisoning. Stress granule-mediated ZBP1 activation drives necroptotic cell death in non-obstructive azoospermia and testicular aging, linking necroptosis to reproductive biology.
Morphological outcome and cell death
In simple terms: The cell swells and bursts, which is the classic necrotic appearance.
The process ends when the cell has died, typically with common morphological features of necrotic cell death. Unlike apoptosis, necroptosis does not require caspase activation and instead depends on RIPK1/RIPK3 and MLKL. The endpoint is plasma membrane rupture, recently shown to involve SIGLEC12.
Key Genes Involved in GO:0070266 necroptotic process
The following genes and proteins are central to the necroptotic process (GO:0070266) and are frequently studied using CRISPR-based models.
| Gene | Major Role | Research Relevance |
|---|---|---|
| RIPK1 | Serine/threonine kinase that initiates necrosome signaling | Core necroptosis regulator; target for knockout and point-mutation studies |
| RIPK3 | Serine/threonine kinase activated in the necrosome | Essential signaling kinase; knockout models block necroptosis |
| MLKL | Executioner protein that permeabilizes the plasma membrane | Critical dependence factor; knockout and knock-in models define execution |
| ZBP1 | Nucleic acid sensor that activates RIPK3 | Links nucleic acid sensing to necroptosis in aging and poisoning models |
| PARP5A | Poly(ADP-ribose) polymerase family member | Phase separation with RNF146 restrains RIPK1-dependent necroptosis |
| RNF146 | E3 ubiquitin-protein ligase | Partners with PARP5A to restrain RIPK1-dependent necroptosis |
| SIGLEC12 | Sialic acid-binding immunoglobulin-like lectin | Mediates plasma membrane rupture during necroptotic cell death |
| TNF | Cytokine that triggers TNF-induced necroptosis | Canonical extracellular trigger of necroptosis |
| TNFRSF1A | TNF receptor superfamily member 1A | Death receptor that initiates necroptotic signaling |
| TLR3 | Toll-like receptor 3 | Toll-like receptor that can trigger necroptosis |
| TLR4 | Toll-like receptor 4 | Toll-like receptor that can trigger necroptosis |
| CASP8 | Caspase 8 | Apoptosis initiator whose inhibition can shift cells toward necroptosis |
| FADD | Fas-associated death domain protein | Adaptor in death receptor signaling relevant to necroptosis |
| TRADD | TNFRSF1A-associated via death domain | Adaptor in TNF receptor signaling relevant to necroptosis |
| CYLD | Deubiquitinase | Regulates RIPK1 ubiquitination and necroptosis sensitivity |
| cIAP1/2 | Cellular inhibitor of apoptosis proteins | Ubiquitin ligases that regulate RIPK1-dependent necroptosis |
| PGAM5 | Phosphoglycerate mutase family member 5 | Mitochondrial regulator implicated in necroptotic signaling |
| DRP1 | Dynamin-related protein 1 | Mitochondrial fission factor linked to necroptotic execution |
How Is necroptotic process Regulated?
Necroptotic process is regulated at multiple levels. RIPK1 ubiquitination and deubiquitination by cIAP1/2 and CYLD control the switch between survival, apoptosis, and necroptosis. PARP5A and RNF146 phase separation restrains RIPK1-dependent necroptosis, providing a phase-separation-based regulatory mechanism. ZBP1 activation downstream of nucleic acid sensing, including mitochondrial DNA release and stress granule formation, regulates RIPK3-dependent necroptosis. SIGLEC12 has been identified as a mediator of plasma membrane rupture during necroptotic cell death, adding a new regulatory node at the execution step. These layers of regulation make necroptosis a highly controlled process that can be tuned by genetic and pharmacological interventions.
necroptotic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| RIPK1 | Cancer progression and therapy response | RIPK1 knockout and point-mutation cell lines |
| RIPK3 | Neurodegeneration in Alzheimer's disease | RIPK3 knockout neurons and knock-in models |
| MLKL | Necroptotic execution in inflammatory disease | MLKL knockout and overexpression models |
| ZBP1 | Non-obstructive azoospermia and testicular aging | ZBP1 knockout germ cell models |
| SIGLEC12 | Plasma membrane rupture in necroptosis | SIGLEC12 knockout and tagged knock-in models |
Necroptosis in cancer progression and therapy
Necroptosis plays complex roles in tumor progression and cancer therapy. It can promote tumor progression in some contexts while also serving as a cell death mechanism that can be exploited therapeutically. The role of necroptosis in cancer biology and therapy is an active area of research, with RIPK1, RIPK3, and MLKL as key nodes.
Necroptosis in neurodegeneration
The necroptosis cell death pathway drives neurodegeneration in Alzheimer's disease. This links GO:0070266 to neurodegenerative disease mechanisms and suggests that inhibiting necroptosis could be neuroprotective.
Necroptosis in inflammatory bowel disease and colorectal cancer
Necroptosis is one of the regulated cell death modalities implicated in inflammatory bowel disease, colorectal cancer, and intestinal injury. The induction mechanisms of ferroptosis, necroptosis, and pyroptosis in these conditions are being dissected to identify therapeutic targets.
Necroptosis in reproductive aging and testicular injury
Stress granule-mediated ZBP1 activation drives necroptotic cell death in non-obstructive azoospermia and testicular aging. This expands the disease relevance of GO:0070266 beyond classical inflammatory and oncological contexts.
From necroptotic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is RIPK1 kinase activity required for necroptosis? | RIPK1 point-mutation (kinase-dead) knock-in cell lines |
| Does MLKL execute plasma membrane rupture? | MLKL knockout and overexpression models |
| Does ZBP1 sense mitochondrial DNA to trigger necroptosis? | ZBP1 knockout cells with mitochondrial DNA stress |
| Does SIGLEC12 mediate plasma membrane rupture? | SIGLEC12 knockout and tagged knock-in cells |
| Does PARP5A/RNF146 phase separation restrain RIPK1-dependent necroptosis? | PARP5A and RNF146 knockout and knock-in models |
| Which genes are essential for TNF-induced necroptosis? | Genome-wide CRISPR knockout library screening |
How to Study the necroptotic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss-of-function of a candidate gene | Testing requirement of RIPK1, RIPK3, MLKL in necroptosis |
| CRISPR point mutation | Specific amino acid change | Testing kinase activity of RIPK1 or RIPK3 |
| CRISPR knock-in | Tagged or reporter allele | Tracking MLKL or SIGLEC12 localization |
| Overexpression | Gain-of-function | Testing sufficiency of ZBP1 or MLKL to trigger necroptosis |
| CRISPR library screening | Genome-wide essentiality | Identifying novel necroptosis regulators |
| Western blotting | Protein expression and phosphorylation | Detecting RIPK1/RIPK3/MLKL activation |
| Imaging | Morphology and membrane integrity | Visualizing plasma membrane rupture |
| Bioinformatics | Pathway and network analysis | Integrating transcriptomic and proteomic data |
Genetic perturbation with CRISPR
CRISPR knockout, point-mutation, knock-in, and overexpression models are used to test causal roles of RIPK1, RIPK3, MLKL, ZBP1, PARP5A, RNF146, and SIGLEC12 in necroptosis. These models allow precise dissection of signaling versus execution phases.
Cell death and viability assays
Necroptotic cell death is measured using viability assays, membrane permeability dyes, and morphological imaging. These assays distinguish necroptosis from apoptosis and other death modalities.
Biochemical analysis of necrosome assembly
Co-immunoprecipitation, western blotting, and phospho-specific antibodies are used to detect RIPK1/RIPK3 activation and MLKL phosphorylation during necroptosis. Phase separation of PARP5A and RNF146 can be assessed by imaging and biochemical fractionation.
Functional genomics and bioinformatics
CRISPR library screening combined with bioinformatics identifies novel regulators of necroptosis. Transcriptomic and proteomic profiling of necroptotic cells reveals pathway crosstalk with ferroptosis and pyroptosis.
How CRISPR Can Be Used to Study GO:0070266 necroptotic process
Knockout
CRISPR knockout of RIPK1, RIPK3, MLKL, ZBP1, PARP5A, RNF146, or SIGLEC12 is used to test whether each gene is required for necroptotic process. Knockout models have established the core dependency of necroptosis on RIPK1/RIPK3 and MLKL.
Point Mutation
Point mutations in RIPK1 or RIPK3 kinase domains are used to separate kinase-dependent signaling from scaffolding functions in necroptosis. Such models help define the signaling phase of GO:0070266.
Knock-in
Knock-in of epitope tags or fluorescent reporters into MLKL, SIGLEC12, or ZBP1 enables real-time tracking of necroptotic execution and membrane rupture. These models are valuable for imaging-based studies.
Overexpression
Overexpression of ZBP1, RIPK3, or MLKL can be used to test sufficiency for triggering necroptosis and to map downstream events. Overexpression models complement knockout studies in establishing causality.
How EDITGENE Supports necroptotic process Research
Researchers studying necroptotic process-related genes often need to determine whether a candidate gene is causally involved in signaling or execution, and CRISPR-based cell models provide the most direct way to test this. EDITGENE offers a comprehensive suite of services to support such studies.
Contact EDITGENE today to design your custom CRISPR model for necroptotic process research.
Frequently Asked Questions About necroptotic process
What is GO:0070266 necroptotic process?
GO:0070266 necroptotic process is a programmed necrotic cell death process triggered by death receptor or Toll-like receptor signaling, characterized by RIPK1/RIPK3 activation and critical dependence on MLKL.
What genes are involved in necroptotic process?
Key genes include RIPK1, RIPK3, MLKL, ZBP1, PARP5A, RNF146, and SIGLEC12, among others.
How is necroptosis different from apoptosis?
Necroptosis is a programmed necrotic cell death that depends on RIPK1/RIPK3 and MLKL, whereas apoptosis typically requires caspase activation.
What is the role of MLKL in necroptosis?
MLKL is the essential executioner that permeabilizes the plasma membrane during the execution phase of necroptosis.
How does ZBP1 trigger necroptosis?
ZBP1 senses nucleic acids, including mitochondrial DNA, and activates RIPK3-mediated necroptosis.
Is necroptosis involved in cancer?
Yes, necroptosis plays complex roles in tumor progression and cancer therapy.
Is necroptosis linked to Alzheimer's disease?
Yes, the necroptosis cell death pathway drives neurodegeneration in Alzheimer's disease.
What experimental models are used to study necroptosis?
CRISPR knockout, point-mutation, knock-in, and overexpression cell models, along with biochemical and imaging assays, are commonly used.
What is the role of SIGLEC12 in necroptosis?
SIGLEC12 mediates plasma membrane rupture during necroptotic cell death.
How can CRISPR screening help identify necroptosis regulators?
Genome-wide CRISPR knockout screens can identify genes required for necroptosis, revealing novel regulators and pathway components.
Conclusion
GO:0070266 necroptotic process is a genetically defined programmed necrotic cell death pathway that is central to inflammation, cancer, neurodegeneration, and reproductive aging. Its core machinery, including RIPK1, RIPK3, MLKL, ZBP1, PARP5A, RNF146, and SIGLEC12, provides multiple entry points for mechanistic and therapeutic studies. CRISPR-based cell models are indispensable for establishing causality and for discovering new regulators of this pathway. As the field moves toward translating necroptosis research into clinical applications, precise genetic tools and rigorous functional assays will be essential. EDITGENE's knockout, point-mutation, knock-in, overexpression, and library screening services are designed to accelerate this work.
References
- 1. Yan J et al.. 2022. Necroptosis and tumor progression.. Trends Cancer 8(1):21-27 PMID: 34627742
- 2. Hou S et al.. 2024. PARP5A and RNF146 phase separation restrains RIPK1-dependent necroptosis.. Mol Cell 84(5):938-954.e8 PMID: 38272024
- 3. Noh H et al.. 2026. SIGLEC12 mediates plasma membrane rupture during necroptotic cell death.. Nature 649(8096):460-466 PMID: 41225007
- 4. Lei H et al.. 2025. Stress granule-mediated ZBP1 activation drives necroptotic cell death in non-obstructive azoospermia and testicular aging.. Proc Natl Acad Sci U S A 122(33):e2514837122 PMID: 40811463
- 5. Balusu S et al.. 2024. The necroptosis cell death pathway drives neurodegeneration in Alzheimer's disease.. Acta Neuropathol 147(1):96 PMID: 38852117
- 6. Gong Y et al.. 2019. The role of necroptosis in cancer biology and therapy.. Mol Cancer 18(1):100 PMID: 31122251
- 7. Lai K et al.. 2024. Sensing of mitochondrial DNA by ZBP1 promotes RIPK3-mediated necroptosis and ferroptosis in response to diquat poisoning.. Cell Death Differ 31(5):635-650 PMID: 38493248
- 8. Zhou P et al.. 2023. The Induction Mechanism of Ferroptosis, Necroptosis, and Pyroptosis in Inflammatory Bowel Disease, Colorectal Cancer, and Intestinal Injury.. Biomolecules 13(5) PMID: 37238692
